BlackRock
CDAK

BlackRock’s Codiak BioSciences, Inc. Common Stock CDAK Stock Holding History

BlackRock’s Portfolio CDAK Stock Details CDAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-187,833
Closed -$74.7K – 5762
2022
Q4 		$74.7K Sell
187,833
-125,089
-40% -$82.3K ﹤0.01% 5126
2022
Q3 		$245K Sell
312,922
-12,261
-4% -$25.7K ﹤0.01% 4925
2022
Q2 		$936K Sell
325,183
-709,012
-69% -$2.49M ﹤0.01% 4558
2022
Q1 		$6.49M Sell
1,034,195
-14,616
-1% -$91.8K ﹤0.01% 3811
2021
Q4 		$11.7M Buy
1,048,811
+122,632
+13% +$1.7M ﹤0.01% 3587
2021
Q3 		$15.1M Buy
926,179
+42,013
+5% +$752K ﹤0.01% 3467
2021
Q2 		$16.4M Buy
884,166
+445,730
+102% +$8.56M ﹤0.01% 3416
2021
Q1 		$6.61M Buy
438,436
+7,434
+2% +$162K ﹤0.01% 3809
2020
Q4 		$13.9M Buy
+431,002
New +$5.7M ﹤0.01% 3199

Other funds holding CDAK

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
FA
Forefront Analytics West Conshohocken, Pennsylvania $110M AUM 18.54% 1-Year Est. Return
PM
Parametrica Management Wanchai, Hong Kong $88M AUM 48.84% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BlackRock's CDAK Position: Q1 2023 in Review

BlackRock sold out of Codiak BioSciences, Inc. Common Stock (CDAK) in Q1 2023, closing a stake of 187,833 shares — an estimated $74.7K sold.

BlackRock first reported a position in CDAK in Q4 2020 and held it in 9 quarters. The position peaked at $16.4M in Q2 2021. 27 funds tracked by Wall St. Rank hold CDAK as of Q1 2023.

  • BlackRock reported no remaining Codiak BioSciences, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • BlackRock sold 187,833 Codiak BioSciences, Inc. Common Stock shares in Q1 2023, an estimated $74.7K.
  • BlackRock first reported a position in Codiak BioSciences, Inc. Common Stock in Q4 2020 and held it in 9 quarters.
  • BlackRock's Codiak BioSciences, Inc. Common Stock position peaked at $16.4M in Q2 2021.
  • 27 funds tracked by Wall St. Rank held Codiak BioSciences, Inc. Common Stock as of Q1 2023.

Based on BlackRock's 13F filing for Q1 2023, filed 12 May 2023.